CureVac (NASDAQ:CVAC) Trading Up 4.7% – Still a Buy?

Shares of CureVac (NASDAQ:CVAC) were up 4.7% on Thursday . The company traded as high as $2.88 and last traded at $2.88. Approximately 363,333 shares were traded during trading, a decline of 56% from the average daily volume of 816,999 shares. The stock had previously closed at $2.75.

Analyst Upgrades and Downgrades

Separately, JMP Securities reiterated a “market outperform” rating and set a $16.00 price target on shares of CureVac in a research report on Monday, September 16th.

CureVac Trading Down 4.0 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The stock has a market cap of $642.54 million, a P/E ratio of 5.22, a PEG ratio of 0.24 and a beta of 2.59. The firm’s fifty day moving average price is $2.84 and its two-hundred day moving average price is $3.18.

Hedge Funds Weigh In On CureVac

A number of institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC purchased a new position in shares of CureVac during the third quarter worth about $30,000. International Assets Investment Management LLC bought a new stake in CureVac during the third quarter valued at approximately $35,000. Integrated Wealth Concepts LLC bought a new stake in CureVac during the third quarter valued at approximately $35,000. Bank of New York Mellon Corp purchased a new position in CureVac in the 2nd quarter worth approximately $54,000. Finally, Ballentine Partners LLC increased its holdings in shares of CureVac by 58.6% in the 3rd quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock worth $67,000 after buying an additional 8,406 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.